7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors 7 Hills safely doses first cancer patient with alintegimod, a novel selective integrin activator designed to improve the efficacy of checkpoint blockade.

7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases